High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: Results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)

Table 3 Baseline characteristics of patients stratified according to HbA1c at baseline

Characteristic	HbA1c <6.5% (n = 86)	HbA1c ≥6.5% (n = 40)	p Value
Males	65 (75.58%)	31 (77.50%)	1.0000^a
Age (years)	62.5 ± 7.9	62.8 ± 7.4	0.8390^b
Body weight (kg)	64.81 ± 10.63	67.65 ± 14.51	0.2176^b
BMI (kg/m²)	24.68 ± 2.71	25.67 ± 4.23	0.1186^b
Lesion length	11.095 ± 3.398	10.213 ± 3.548	0.1835^b
Lesion location
Proximal	15 (17.44%)	18 (45.00%)
Distal	33 (38.37%)	7 (17.50%)
Other	38 (44.19%)	15 (37.50%)
Target vessel
RCA	35 (40.70%)	16 (40.00%)
LAD	25 (29.07%)	13 (32.50%)
LCX	26 (30.23%)	10 (25.00%)
LMT	0 (0.00%)	1 (2.50%)
LLT before enrolment	62 (72.09%)	30 (75.00%)	0.8308^a
Hypertension	65 (75.58%)	31 (77.50%)	1.0000^a
Smoking	22 (25.58%)	14 (35.00%)	0.2954^a
Diabetes mellitus	9 (10.47%)	38 (95.00%)	<0.0001^a
Family history of CAD	19 (22.09%)	7 (17.50%)	0.6411^a
Concomitant therapy
Ca channel blocker	46 (53.49%)	26 (65.00%)	0.2507^a
Nitrate	57 (66.28%)	24 (60.00%)	0.5512^a
ACE inhibitor	16 (18.60%)	11 (27.50%)	0.3507^a
ARB	39 (45.35%)	17 (42.50%)	0.8481^a
β-blocker	22 (25.58%)	7 (17.50%)	0.3697^a
Thiazolidinedione	0 (0.00%)	9 (22.50%)	<0.0001^a
Sulfonylurea	3 (3.49%)	18 (45.00%)	<0.0001^a
α-glucosidase inhibitor	4 (4.65%)	17 (42.50%)	<0.0001^a
Insulin	1 (1.16%)	10 (25.00%)	<0.0001^a
Ticlopidine	83 (96.51%)	38 (95.00%)	0.6522^a
Clopidogrel	5 (5.81%)	2 (5.00%)	1.0000^a
Aspirin	86 (100.00%)	40 (100.00%)	1.0000^a

Data are means ± SD or n (%).
^aχ² or Fisher’s exact test; ^btwo-sample t-tests.
RCA, right coronary artery; LAD, left anterior descending; LCX, left circumflex; LMT, left main trunk; LLT, lipid-lowering therapy; CAD, coronary heart disease; HDL-C, HDL-cholesterol; IVUS, intravascular ultrasound; ARB: angiotensin receptor blocker.

ISSN: 1475-2840